{"nctId":"NCT00402363","briefTitle":"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","startDateStruct":{"date":"2006-11"},"conditions":["Fibrillation, Atrial"],"count":663,"armGroups":[{"label":"omega-3-acid ethyl esters","type":"EXPERIMENTAL","interventionNames":["Drug: omega-3-acid ethyl esters"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"omega-3-acid ethyl esters","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women age 18 years or older\n* History of symptomatic atrial fibrillation (either paroxysmal or persistent)\n* Provide written informed consent and authorization for protected health information disclosure\n\nExclusion Criteria:\n\n* Permanent (chronic) atrial fibrillation\n* Antiarrhythmic drug therapy which cannot be stopped\n* Use of amiodarone with prior 6 months\n* History of unsuccessful cardioversion\n* History of certain cardiovascular conditions or cardiac surgery within prior 6 months\n* History of stroke within prior 6 months\n* Implanted cardio-defibrillator\n* Certain circulatory, thyroid, pulmonary, liver, kidney, musculoskeletal or metabolic conditions, or cancer (except non-melanoma skin cancer)\n* Poorly controlled diabetes","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter","description":"A documented episode of symptomatic AF /Flutter was defined as AF/Flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Persistent AF and in Both AF Subgroups Combined With an Event of Documented Symptomatic AF/Flutter","description":"A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"147","spread":null},{"groupId":"OG003","value":"167","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"176","spread":null},{"groupId":"OG003","value":"155","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Paroxysmal AF or Persistent AF With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter)","description":"A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic AF.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"133","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"125","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter)","description":"A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic AF.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"163","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]}]},{"type":"SECONDARY","title":"Number Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF/Flutter","description":"A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"153","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF/Flutter","description":"A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"129","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter)","description":"A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"151","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter)","description":"A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"133","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Paroxysmal or Persistent AF With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter","description":"A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"34","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in the Combined AF Subgroups With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter","description":"A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null},{"groupId":"OG001","value":"148","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Paroxysmal or Persistent AF With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter)","description":"A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic AF.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"34","spread":null},{"groupId":"OG003","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in the Combined AF Subgroups With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter)","description":"A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. \"Censored\" in the table below refers to participants who did not have a documented episode of symptomatic AF.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Number of AF/Flutter Rescue Episodes During the Treatment Period","description":"Rescue was defined as any pharmacological/electrical/surgical intervention for the termination/prevention of AF/flutter with a maximum of one rescue episode counted per day. Note: all annualized values were calculated by counting the number of rescue episodes, dividing by the number of days on treatment, then multiplying that number by 365.25.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.44","spread":null},{"groupId":"OG001","value":"4.17","spread":null},{"groupId":"OG002","value":"2.17","spread":null},{"groupId":"OG003","value":"2.24","spread":null},{"groupId":"OG004","value":"2.19","spread":null},{"groupId":"OG005","value":"4.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Cumulative Frequency of Symptomatic AF/Flutter Recurrences During the Treatment Period","description":"Values were annualized by counting the number of episodes of symptomatic AF/flutter recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.81","spread":null},{"groupId":"OG001","value":"8.32","spread":null},{"groupId":"OG002","value":"4.22","spread":null},{"groupId":"OG003","value":"4.35","spread":null},{"groupId":"OG004","value":"6.48","spread":null},{"groupId":"OG005","value":"6.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Cumulative Frequency of Symptomatic AF Recurrences During the Treatment Period","description":"Values were annualized by counting the number of episodes of symptomatic AF recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.91","spread":null},{"groupId":"OG001","value":"8.30","spread":null},{"groupId":"OG002","value":"4.22","spread":null},{"groupId":"OG003","value":"4.35","spread":null},{"groupId":"OG004","value":"6.48","spread":null},{"groupId":"OG005","value":"6.52","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":331},"commonTop":["Nausea","Urinary tract infection","Dizziness","Sinusitis","Diarrhea"]}}}